Agenus Inc. P/S ratio

P/S ratio of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Current P/S ratio of Agenus Inc. is 3.66 (as of December 30, 2019)
  • P/S ratio for the quarter ending June 29, 2020 was 6.89 (a 65.26% increase compared to previous quarter)
  • Year-over-year quarterly P/S ratio increased by 136.63%
  • Annual P/S ratio for 2019 was 3.66 (a -48.92% decrease from previous year)
  • Annual P/S ratio for 2018 was 7.17 (a -11.79% decrease from previous year)
  • Annual P/S ratio for 2017 was 8.13 (a -49.36% decrease from previous year)
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of Agenus Inc.

Most recent P/S ratioof AGEN including historical data for past 10 years.

Interactive Chart of P/S ratio of Agenus Inc.

Agenus Inc. P/S ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 6.89 4.17
2019 3.66 2.91 3.45 3.29 3.66
2018 7.17 6.72 8.7 26.64 7.17
2017 8.13 11.78 9.42 8.09 8.13
2016 16.05 25.42 13.03 13.44 16.05
2015 14.31 20.7 48.78 33.5 14.31
2014 34.0 33.98 40.95 60.32 34.0
2013 25.8 22.46 27.45 26.06 25.8
2012 6.07 7.23 8.07 10.17 6.07
2011 15.67 18.37 28.91 33.18 15.67
2010 29.06 33.68 24.36 18.2 29.06
2009 15.17 0.0 15.17

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.